Audit: QRS - UV Blood Irradiation for Health & Longevity
Audit conducted on 10/08/2026 07:06 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 91 |
| Passed | 82 |
| Failed | 0 |
| N/A | 9 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All protocol values (50–100 mL, 6–10 sessions, 1–2 J/cm², 200 ng/mL, 254 nm, 1.5 mL per pound), time-to-effect values (3–4 months, 24–76 hours, 1–3 sessions), benefit/risk headings, contraindications, interactions, and biomarker targets trace to ER lines 385–405, 442, 155–229, 251–317, 341–361, 468–489. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “no objective marker has been shown to change on any defined timeline in a controlled setting” (time_3_sub), “uncontrolled mid-century case series” (time_2_sub), and “Described by clinics” mirror ER lines 442 and 144. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Absolute contraindications remain absolute and “Strong caution” items retain the ER’s own “Strong caution” prefix (ER lines 357–361). |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come from ER “Populations who should avoid this intervention”, Key Interactions from the ER interaction bullets, Risks from “Potential Risks & Side Effects”; no Benefit- or Risk-Modifying Factor is promoted into a gate. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT identifiers, author names, or brand names (e.g., Therakos) appear anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | The only attributions are “Described by clinics” (time_3_sub), matching ER line 442. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Sober, evidence-grading tone with explicit uncertainty markers, matching the ER’s Conclusion and Benefits framing. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantified protocol cells, tiered benefit/risk lists, and a concrete monitoring panel give the reader actionable decision material without hedging into vagueness. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is stated as evidence and observed practice (“Described by clinics”, “Historical acute-infection use was 1–3 sessions total”), not as instruction. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No “should”, “must”, “recommend”, or “advise” appears in the QRS body. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Monitoring cadence and protocol cells are stated descriptively as what the ER documents, not as directives. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns occur anywhere in the QRS. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain-language substitutions carried over from the ER: “estimated filtering capacity” for eGFR, “white cells”, “light-sensitizing drug”. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every list item is a condensed heading or key fact; all mechanistic prose from the ER is stripped. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed: no direct address in any populated variable. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Contraindication thresholds, interaction lists, and a nine-marker monitoring panel address a risk-aware self-directed reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Front-loaded lab cadence, session schedules, and qualitative logging assume willingness to undertake effortful tracking. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Assumes access to specialist assays (G6PD activity, ANA, haptoglobin) and interpretation of functional ranges. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-a-glance closes on “Nothing has been measured in healthy people”, the decisive fact for a longevity-oriented reader, matching ER line 521. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” does not occur; the title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Uses “hemolysis”, “cytopenias”, “extracorporeal circulation”, “photosensitivity”, “apheresis-collected white cells”; no consumer-grade substitutes. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | Verified at lines 446, 492, 543, 638, 670, 824 (headings), 573, 599 (gates), 548/554/561 and 643/649/656/661 (tier labels), 674–676 (table headers). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | 67 named variable spans present, covering every variable the checklist defines: page/header (4), at_a_glance, action_1–3 (label/value/sub), time_1–3 (label/value/sub), benefits and risks tiers (8), stop_items, caution_items, marker_1–9 (name/target/why), monitoring_cadence, qualitative_item_1–6. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | No extraneous or invented spans; template-only markers (<span website="evidence_review">, website="full_review", website="audit") are untouched at lines 423, 426, 440. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section is empty and the ER uses no empty-state phrasing; the one tier without items (Benefits: High) is governed by item 12.5. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | action_1_label “The classical extracorporeal protocol”, action_2_label “Course length and frequency”, action_3_label “The drug-assisted hospital protocol” match ER lines 385, 393, 389; interaction labels match ER lines 341–353 with the em-dash clauses stripped per item 9.4. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Marker names reproduce ER table row names (ER lines 470–478); contraindication and interaction labels reproduce ER wording. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji present; the ER’s “⚠️ Conflicted” markers on two Low benefits were correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to headings or single key facts against a 526-line ER; no mechanistic prose, magnitudes, or “Context/Notes” content is carried over. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14, immediately after <!doctype html> at line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3, closing --- at line 13; the descriptive text at line 2 precedes the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is repeated in the header, footer, or body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, and it contains a colon requiring quoting. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: uv_blood_irradiation_2026-0810-0245_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0810-0635. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: uv_blood_irradiation_2026-0810-0245_Opus_QRS.html, matching the actual filename. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “UV Blood Irradiation for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “UV Blood Irradiation for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “08/10/2026”, from qrs_creation_date 2026-0810-0635. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header contains only the title and the template subline; the ER’s alternate-names line is not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Compresses the Conclusion’s four load-bearing points — what is done, the mechanism, hospital-form evidence quality, clinic-form evidence quality, absence of healthy-population data (ER lines 517–521). |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | Exactly 60 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | “small share of blood, then returned” (ER 517); “changed immune cell behaviour, not direct microbe killing” (ER 517); “response in steroid-resistant disease, almost all from studies without comparison groups” (ER 519); “clinic version rests on reports without comparison groups” (ER 519); “Nothing has been measured in healthy people” (ER 521). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “light-sensitizing drug”, “comparison groups”, and “immune cell behaviour” replace psoralen, controlled trials, and immunomodulation. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, sample sizes, or p-values. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numeric results of any kind. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All nine items map to ER lines 357–361 (“Populations who should avoid this intervention”). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | Absolute (porphyria, psoralen reaction, aphakia, pregnancy/breastfeeding, active melanoma), drug-assisted absolutes, and all three “Strong caution” groups are present. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Nine <li> elements at lines 576–594. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | ER rationales “at which the extracorporeal volume becomes a large fraction of circulating volume”, “because of impaired citrate handling”, “in which the volume shifts of extracorporeal circulation are poorly tolerated”, and “where the risk is displacement of effective treatment” are all stripped; no dash-trailing clauses remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Retains hemoglobin <10 g/dL, platelets <20,000/µL, white cells <1,000/µL, weight <40 kg, filtering capacity <30 mL/min/1.73 m², myocardial infarction within 90 days, NYHA Class IV, and the “(drug-assisted version)” scope qualifier. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in its contraindication list. |
| 8.7 | If no [stop_items] are present the section is left empty | N/A | Nine stop_items are present. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All seven items map one-to-one to the ER interaction bullets at lines 341–353. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All seven ER interaction bullets are present; none duplicates a contraindication item. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Seven <li> elements at lines 602–628. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s em-dash clauses (“— caution, with timing separation”, “— potentially antagonistic, separate by 24 hours”, “— additive, and commonly combined deliberately”, “— monitor, direction uncertain”) are stripped, as is all mitigation prose. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Named example drugs are preserved for every class: doxycycline, ciprofloxacin, amiodarone, hydrochlorothiazide, chlorpromazine, voriconazole; tretinoin, ibuprofen, glycolic acid; warfarin, apixaban, rivaroxaban, clopidogrel, aspirin; tacrolimus, cyclosporine, prednisone, ruxolitinib, pembrolizumab, nivolumab. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in its interaction bullets. |
| 9.7 | If no [caution_items] are present the section is left empty | N/A | Seven caution_items are present. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells derive from ER “Therapeutic Protocol” lines 385, 389, 393. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Covers the classical extracorporeal protocol (the form the ER’s benefit and risk profile is built on), course length and frequency, and the drug-assisted hospital protocol (the only regulator-reviewed dosing standard in the ER). |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER Protocol section contains more than three distinct actionable aspects; all three sets are populated. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | Values 50–100 mL, 6–10 sessions, and 1–2 J/cm² ultraviolet A with their subs all trace verbatim to ER lines 385, 389, 393. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Graft-versus-host response, historical acute infection, and classical subjective change are precisely the three aspects in ER line 442. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered Medium (graft-versus-host disease, ER line 169), Low (adjunctive effect in serious bacterial infection, ER line 207), Speculative (fatigue/wellbeing, ER line 219). |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects exist in the ER; all three sets are populated. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | 3–4 months, 24–76 hours, and 1–3 sessions with their qualifying subs all derive from ER line 442 (with the case-series characterization from ER line 144). |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information at line 442; the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Every listed item is an ER #### benefit heading from lines 163–229. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present at lines 545, 546, 552, 560. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Only the benefit headings are carried; all Magnitude figures (73% response, 45–58% pooled response, 21.5% viral load reduction, 0.91 vs 1.44 rejection episodes) are omitted. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any benefits span. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER High tier has no benefit items (ER line 159); line 545 sets benefits_high to style="display: none" with empty content. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Every listed item is an ER #### risk heading from lines 253–317. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present at lines 640, 647, 654, 659. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Only headings are carried; the 5–30% phlebitis rate, 0.5 per 1,000 catheter-days, 0.38 severe-event rate, and USD 150–400 pricing are all omitted. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any risks span. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER risk tiers contain items, so no risks span needs to be hidden. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Table rows and cadence derive from ER “Monitoring Protocol & Defining Success” lines 468–480. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All nine ER biomarker rows present: G6PD enzyme activity, haptoglobin, lactate dehydrogenase, complete blood count with differential, high-sensitivity C-reactive protein, ferritin, comprehensive metabolic panel, antinuclear antibody, hepatitis B/C and HIV serology — with targets matching ER lines 470–478. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Line 813 reproduces the ER’s front-loaded schedule from line 480: haptoglobin/LDH/CBC within 48 hours, after the third session, and at end of series; hsCRP and CBC every 3 months; metabolic panel every 6 months. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All six items derive from the qualitative marker list at ER lines 484–489. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six present: daytime energy/afternoon crash, sleep quality and duration, minor infection frequency, post-session symptoms, exercise capacity at fixed workload, joint stiffness and pain scores. |
Issues 10/08/2026 07:06
Pass rate 100.00%. No issues found.
Issues 10/08/2026 06:53
- 4.5 — Sheet exceeds one A4 page: The populated sheet renders well beyond a single A4 page; the decision gates, the 9-row Monitoring table with multi-line “Why” cells, and the 3-sentence Cadence paragraph (lines 819-825) are the main overruns and need condensing rather than spilling onto a second page.
Fixes 10/08/2026 06:53
- 4.5 — Key Interactions condensed: Stripped the redundant drug-class wrappers from the two photosensitizer items, keeping every named example drug (“tetracyclines (doxycycline), fluoroquinolones (ciprofloxacin)…” → “doxycycline, ciprofloxacin…”; “retinoids (tretinoin), non-steroidal anti-inflammatory drugs (ibuprofen), alpha-hydroxy acid preparations (glycolic acid)” → “tretinoin, ibuprofen, glycolic acid”), and reduced “corticosteroids (prednisone)” to “prednisone”.
- 4.5 — Contraindications tightened: Trimmed three gate items without dropping any threshold or qualifier — “Documented idiosyncratic reaction…” → “Idiosyncratic reaction…”, the lupus/albinism item to a parenthetical form, and “body weight”/”estimated glomerular filtration rate” to “weight”/”estimated filtering capacity” (the ER’s own monitoring wording).
- 4.5 — Monitoring “Why” cells shortened: Condensed three multi-line rationales to single lines (complete blood count, comprehensive metabolic panel, antinuclear antibody), preserving the stated reason for each marker.
- 4.5 — Cadence paragraph condensed: Rewrote the cadence sentence more compactly (“again after the third, then at the end of the initial series; … at the end of the initial series and, if sessions continue, every 3 months thereafter” → “after the third, and at the end of the initial series; … then every 3 months if sessions continue”), keeping every interval unchanged.
Issues 10/08/2026 06:45
- 7.4 — Specialist term in At-A-Glance: “The clinic version rests on uncontrolled reports” (line 437) uses “uncontrolled” in its research-methodology sense, which a non-specialist would not read correctly, while the same paragraph already expresses the concept plainly as “studies without comparison groups”.
Fixes 10/08/2026 06:45
- 7.4 — Specialist term in At-A-Glance: Replaced “rests on uncontrolled reports” with “rests on reports without comparison groups” and tightened “not direct killing of microbes” to “not direct microbe killing” to stay within the 60-word budget.
Issues 10/08/2026 06:41
- 4.2 / 4.3 — Protocol labels paraphrased: The three Protocol cell labels (lines 450, 464, 478) are rewritten rather than taken verbatim from the ER’s bold bullet labels — “Classical extracorporeal” vs “The classical extracorporeal protocol” (ER line 385), “Course length & frequency” vs “Course length and frequency” (ER line 393), and “Drug-assisted hospital form” vs “The drug-assisted hospital protocol” (ER line 389).
- 9.5 — Example drugs dropped from interactions: The named example drugs the ER gives in parentheses are dropped entirely from the photosensitizing prescription medications item (line 603) and the over-the-counter photosensitizers item (line 607), and partially from the immunosuppressants item (line 627), although 9.5 requires them to be shortened rather than dropped.
Fixes 10/08/2026 06:41
- 4.2 / 4.3 — Protocol labels made verbatim: Restored the ER’s bold bullet labels in the three Protocol cells — “Classical extracorporeal” to “The classical extracorporeal protocol”, “Course length & frequency” to “Course length and frequency”, and “Drug-assisted hospital form” to “The drug-assisted hospital protocol”.
- 9.5 — Example drugs restored to interactions: Added one concise ER example drug per class where the list had been dropped — doxycycline, ciprofloxacin, hydrochlorothiazide, and chlorpromazine to the photosensitizing prescription medications item; tretinoin, ibuprofen, and glycolic acid to the over-the-counter photosensitizers item; and prednisone to the systemic immunosuppressants item.